Mixed results for experimental Alzheimer's therapies at CTAD
This year's Clinical Trials on Alzheimer's Disease (CTAD) congress in Boston has revealed encouraging data for new drug candidates from the likes of Biogen and AriBio, but some disappointments as well.
AriBio's daily pill shows glimmers of efficacy
AriBio reported that its oral PDE5 inhibitor AR1001 slowed cognitive decline by 31% compared to placebo over 52 weeks when used as a monotherapy in the phase 3 POLARIS-AD trial. However, the overall result – including patients also taking drugs like cholinesterase inhibitors at baseline – numerically favoured the drug but fell short of achieving statistical significance.
Secondary cognitive and functional measures also trended towards improvement with AR1001 in the 1,535-patient study, with one – the Mini-Mental State Examination (MMSE) scale – just clearing the threshold for a statistically significant improvement. AriBio said that it will now discuss the data with the FDA to see if there is a regulatory pathway to approval for the drug, which it wants to position as "an oral treatment that could slow Alzheimer's progression and be practical for patients and care partners to use over the long term."
At the moment, disease-modifying drugs for Alzheimer's – namely amyloid-targeting antibodies Leqembi (lecanemab) from Eisai/Biogen and Kisunla (donanemab) from Eli Lilly – have to be delivered either intravenously or by injection. AR1001 could also offer a novel mechanism, relaxing blood vessels to increase blood flow to the brain.
Two-year results back tau-targeting drug from Biogen
Biogen announced two-year results at CTAD from the phase 2 CELIA trial of anti-tau antisense oligonucleotide diranersen (BIIB080), showing that a 60 mg, twice-yearly dose was able to slow clinical decline – measured using the CDR-SB scale – by 38% in people living with early-stage Alzheimer's. A one-point difference on CDR-SB is generally considered highly meaningful by clinicians.
Lead investigator Lawren VandeVrede of the University of California, San Francisco, said the result at 96 weeks was " highly encouraging," particularly as the efficacy curves show increasing separation with placebo after the 18-month timepoint. "For patients and families, slowing clinical decline means more time in early stages, preserving independence, and remaining connected to the people and experiences that matter most," he told the meeting.
Biogen – which licensed diranersen from Ionis – said the phase 2 findings support the continued development of diranersen and further evaluation in a phase 3 trial due to start next year. An earlier readout from the trial at 76 weeks disappointed investors, in part because the results did not show a dose response, with higher doses of the drug less effective.
Long-term follow-up data build case for Leqembi
While Leqembi is considered to have fairly modest efficacy, Eisai and Biogen reported new five-year data from the CLARITY AD trial, which supported the drug's regulatory approvals, suggesting that the drug's benefits continue to accrue over time in early Alzheimer's.
The new results showed that continuous treatment with Leqembi reduced the relative risk of progressing to the next stage of Alzheimer's by 36% compared to natural history cohorts.
Meanwhile, Eisai and Biogen also presented a new analysis of the real-world LEADER trial in 560 patients with early Alzheimer's in the US, which showed a 76% lower rate of progression to moderate or severe Alzheimer's disease dementia with Leqembi, compared to a matched natural history cohort, at three years. All told, 81.1% of patients remained stable or improved at roughly 18 months, with models projecting 95% stay in early-stage disease through three years.
After a slow start in the marketplace, held back by perceptions of limited efficacy alongside a small risk of severe side effects, Leqembi has started to build sales momentum, bringing in $554 million globally in the first nine months of the year.
Signs of efficacy for BMS' Cobenfy in Alzheimer's psychosis
Initial data from the ADEPT clinical trial programme of Bristol Myers Squibb's dual M1/M4 muscarinic agonist Cobenfy (xanomeline and trospium chloride) for Alzheimer's disease psychosis showed encouraging improvements in hallucination and delusion scores alongside favourable long-term tolerability, with a three-times-daily dosing schedule.
The preliminary results come from a 12-week open-label study (ADEPT-1) and a 12-month extension (ADEPT-3), which both showed reductions in the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D) and Clinical Global Impression-Severity (CGI-S) scales. The main readout from the programme is due in early 2027, having been delayed from this year.
First approved for schizophrenia in 2024, Cobenfy has had a sluggish start commercially – it made just $176 million in the first nine months of the year – and BMS is looking to the Alzheimer's psychosis indication to improve its prospects. Analysts at Jefferies have suggested that use in Alzheimer's could unlock sales potential of $2.6 billion a year.
Another drug being developed for Alzheimer's psychosis, Acadia Pharma's serotonin 5-HT2A receptor inverse agonist remlifanserin, narrowly missed its objectives in the phase 2 RADIANT trial reported at CTAD, but the company thinks there was enough of an efficacy signal to warrant a phase 3 trial programme.
Cognito's digital therapeutic misses the mark
In the digital health space, Cognito Therapeutics faced a setback at CTAD after results from the phase 3 HOPE trial showed that its Spectris AD at-home headset failed to slow cognitive decline in people living with mild-to-moderate Alzheimer's. The device uses light and sound to try to restore gamma waves in the brain, linked to memory and attention, that seem to be compromised in this type of dementia.
There were signs of greater efficacy in a subgroup of patients with mild Alzheimer's, with a nominally significant slowing of decline on the CDR-SB scale as well as measures of daily function and instrumental activities of daily living. As that points to a possible effect in earlier-stage disease, Cognito plans to discuss a potential path to approval for Spectris AD in these patients.
Photo by jacob Licht on Unsplash
